Affordable Access

deepdyve-link
Publisher Website

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.

Authors
  • Heinzerling, L
  • Baiter, M
  • Kühnapfel, S
  • Schuler, G
  • Keikavoussi, P
  • Agaimy, A
  • Kiesewetter, F
  • Hartmann, A
  • Schneider-Stock, R
Type
Published Article
Journal
British Journal of Cancer
Publisher
Springer Nature
Publication Date
Nov 26, 2013
Volume
109
Issue
11
Pages
2833–2841
Identifiers
DOI: 10.1038/bjc.2013.622
PMID: 24196789
Source
Medline
License
Unknown

Abstract

As heterogeneity with respect to BRAF mutation status is detected in melanoma patients, subsequent testing of initially wild-type patients can yield different results and thus make BRAF inhibitor therapy accessible. The role of heterogeneity in testing and for clinical response to therapy with a BRAF inhibitor needs to be further investigated.

Report this publication

Statistics

Seen <100 times